Barclays analyst Charles Pitman CFA maintained a Buy rating on Lonza Group Ltd (LONN – Research Report) today and set a price target of ...

Lonza Group AG / Key word (s): Miscellaneous Lonza Implements its Simplified and Streamlined Operating Model 01.04.2025 / 14:00 CET/CEST ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Lonza, the Swiss Biotech firm that purchased Vacaville’s Genentech plant from Roche in 2024, released a streamlined operating model and invitations to its Annual General Meeting in Basel, ...

The extended agreement will expand the dedicated bioconjugation footprint for the customer through the construction of a new bioconjugation suite at Lonza’s Ibex ® Biopark in Visp (CH). In addition, ...

There are limited tariff risks. Lonza is a potential beneficiary given the ample availability of the USA industrial capacities should biotech or pharma have onshoring needs. With profit growth ...

The issuer is solely responsible for the content of this announcement. Basel, Switzerland, 3 April 2025 – Lonza today announced the publication of its 2024 Annual and Sustainability Reports, as well ...

On Wednesday, Morgan Stanley (NYSE:MS) analysts adjusted their stance on Lonza Group (LONN:SW) (OTC: LZAGY), downgrading the stock from Overweight to Equalweight, while increasing the price target ...

All trademarks belong to Lonza and are registered in CH, US and/or EU, or belong to their respective third-party owners and are used only for informational purposes. PharmiWeb.com is Europe's leading ...